Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 60,444,618 | 50,623,645 | 98,343,956 | 105,993,785 | 68,998,263 | 384,404,267 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 60,444,618 | 50,623,645 | 98,343,956 | 105,993,785 | 68,998,263 | 384,404,267 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 133,730,186 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 250,674,081 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 60,444,618 | 50,623,645 | 98,343,956 | 105,993,785 | 68,998,263 | 384,404,267 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 2,057,158 | 2,818,334 | 1,722,957 | 1,346,882 | 2,204,173 | 10,149,504 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support. Add lines 7 through 10 | 394,553,771 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2022 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2022 |
(iii) Distributable Amount for 2022 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2022 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2022 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2022: | ||||
| a From 2017....... | ||||
| b From 2018....... | ||||
| c From 2019....... | ||||
| d From 2020....... | ||||
| e From 2021....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2022 distributable amount | ||||
|
i
Carryover from 2017 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2022 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2022 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2022, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2022. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2023. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2018..... | ||||
| b Excess from 2019..... | ||||
| c Excess from 2020..... | ||||
| d Excess from 2021..... | ||||
| e Excess from 2022..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS CONTINUED: | NIMBLE'S INNOVATIVE APPROACH HAS ALREADY SHOWN INCREDIBLE POTENTIAL FOR REVOLUTIONIZING MEDICAL RESEARCH AND PATIENT CARE. AS A RESULT OF THE INITIATIVE'S ACHIEVEMENTS, NUMEROUS ABSTRACTS WERE PRESENTED AT THE ANNUAL AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD) CONFERENCE AND THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (EASL) CONFERENCE. MOREOVER, CORRESPONDENCE WAS PUBLISHED IN THE HIGH-IMPACT JOURNAL NATURE MEDICINE HIGHLIGHTING THE PROGRAM'S FINDINGS TO DATE. STRENGTHENING THE PATIENT VOICE WITH DIGITAL MEASURES WORKSHOPS OVER THE PAST FEW YEARS, THE FNIH BIOMARKERS CONSORTIUM HAS LAUNCHED A SERIES OF DIGITAL MEASURES WORKSHOPS DESIGNED TO BRING REGULATORS, PAYERS, AND PATIENTS TOGETHER TO STREAMLINE DIGITAL MEASURE DEVELOPMENT AND IMPLEMENTATION PROCESSES. THE FIRST WORKSHOP, WHICH WAS CONDUCTED IN FEBRUARY 2020, WAS INSTRUMENTAL IN HELPING THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) BRING FORWARD THE INNOVATIVE SCIENCE AND TECHNOLOGY APPROACHES FOR NEW DRUGS (ISTAND) PROGRAM. THE WORKSHOP ALSO HELPED THE FDA REDEFINE ITS NOMENCLATURE AROUND DIGITAL HEALTH AND BIOMARKERS AND FOCUS ON DIGITAL MEASURES. THE FNIH BIOMARKERS CONSORTIUM HOSTED ITS SECOND DIGITAL MEASURES WORKSHOP SEPTEMBER 2022 IN ZURICH, SWITZERLAND, WITH A GOAL OF EMPHASIZING PATIENT-CENTRICITY IN SHAPING AND IMPROVING HOW DIGITAL MEASURES ARE IDENTIFIED, DESIGNED, AND IMPLEMENTED. THIS WORKSHOP ESTABLISHED A GLOBAL FOOTPRINT FOR FNIH AND ITS PARTNERS, ENGAGING THE EUROPEAN MEDICINES AGENCY (EMA) AND OTHER INTERNATIONAL PARTNERS IN A WAY THAT HADN'T BEEN PREVIOUSLY POSSIBLE. A THIRD FUTURE WORKSHOP WILL PROVIDE THE CRITICAL LINK BETWEEN NIH, REGULATORS, AND INDUSTRY TO ENSURE THAT ALL PLAYERS HAVE A SEAT AT THE TABLE, THAT PATIENTS ARE INCLUDED, AND THAT THE FIELD CAN COLLECTIVELY IDENTIFY PROCESSES AND CHECKS SO THAT DIGITAL HEALTH LEADS TO USEFUL TOOLS, NOT JUST MORE GADGETS. RESEARCH PROGRAMS FOR ADVANCING GLOBAL HEALTH PREVENTING SEPSIS IN LABORING MOTHERS WORLDWIDE MATERNAL AND NEONATAL SEPSIS IS ONE OF THE TOP THREE CAUSES OF MATERNAL AND NEWBORN DEATHS GLOBALLY. TO ADDRESS THIS PRESSING ISSUE AND URGENT GLOBAL NEED, THE AZITHROMYCIN PREVENTION IN LABOR USE STUDY (A-PLUS) WAS CONDUCTED BY THE EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT (NICHD)'S GLOBAL NETWORK FOR WOMEN'S AND CHILDREN'S HEALTH RESEARCH AND WAS CO-FUNDED BY NICHD AND THE FNIH, WITH SUPPORT TO THE FNIH PROVIDED BY A GRANT FROM THE BILL & MELINDA GATES FOUNDATION. THE STUDY ASSESSED LOW-COST, SUSTAINABLE INTERVENTIONS TO IMPROVE MATERNAL AND CHILD HEALTH IN LOW- AND MIDDLE-INCOME COUNTRIES. AFTER A RIGOROUS PROCESS OF TRAINING AND PILOT-TESTING, INVESTIGATORS EXAMINED THE SAFETY AND EFFECTIVENESS OF A SINGLE ORAL DOSE OF AZITHROMYCIN ADMINISTERED DURING LABOR (COMPARED TO PLACEBO) IN REDUCING THE RISK OF NEONATAL AND MATERNAL SEPSIS OR DEATH IN LABORING WOMEN. THE RESULTS WERE VERY PROMISING, SUGGESTING THAT AZITHROMYCIN CAN REDUCE THE OCCURRENCE OF MATERNAL SEPSIS AND DEATH BY APPROXIMATELY ONE-THIRD. FOLLOWING THE STUDY, INVESTIGATORS RAPIDLY ANALYZED THE QUALITY OF THE DATA AND RESULTS TO ENABLE OPEN ACCESS TO THE FINDINGS IN A TIMELY MANNER. AN ABSTRACT WAS SUBMITTED TO THE WORLD'S PREMIER PREGNANCY CONFERENCE, THE SOCIETY FOR MATERNAL-FETAL MEDICINE'S ANNUAL PREGNANCY MEETING (SMFM). THE ABSTRACT WAS ACCEPTED AND BECAME THE #1 LATE-BREAKING PRESENTATION AT THE CONFERENCE IN FEBRUARY 2023. THE STUDY INVESTIGATORS ALSO SUBMITTED A MANUSCRIPT TO THE NEW ENGLAND JOURNAL OF MEDICINE (NEJM), WHICH WAS ACCEPTED AND PUBLISHED AS THE CONFERENCE PRESENTATION WAS BEING DELIVERED. AS A NEXT STEP, THE A-PLUS INVESTIGATORS WILL FOLLOW UP WITH A SUBSET OF THE MOTHERS AND INFANTS TO EXAMINE POTENTIAL ANTIMICROBIAL RESISTANCE AT MULTIPLE POINTS IN TIME, UP TO A YEAR AFTER INITIAL DELIVERY, AS A FURTHER SAFETY MEASURE. THE STUDY FINDINGS COULD RESULT IN A CHANGE TO THE CURRENT STANDARD OF CARE BY ADDING THIS SIMPLE PREVENTIVE INTERVENTION AN ADJUSTMENT THAT COULD SAVE MILLIONS OF LIVES. REDUCING ANEMIA IN POSTPARTUM WOMEN IRON DEFICIENCY ANEMIA REMAINS A MAJOR CONTRIBUTOR TO MATERNAL ILLNESS AND MORTALITY WORLDWIDE, AND DESPITE NUMEROUS EFFORTS, RATES OF ANEMIA HAVE NOT DECREASED IN LOW- AND MIDDLE-INCOME COUNTRIES. THANKFULLY, INTRAVENOUS IRON TREATMENTS HAVE BEEN DEMONSTRATED TO BE A SAFE, EFFECTIVE INTERVENTION TO REDUCE ANEMIA DURING PREGNANCY. HOWEVER, INTRAVENOUS IRON TREATMENTS HAVE NOT BEEN COMPREHENSIVELY ASSESSED DURING THE POSTPARTUM PERIOD UNTIL NOW. FIRST LAUNCHED IN NOVEMBER 2022, THE PREVENTION OF IRON DEFICIENCY ANEMIA POST-DELIVERY (PRIORITY) TRIAL AIMS TO DETERMINE IF A SINGLE-DOSE INTRAVENOUS IRON INFUSION IS MORE EFFECTIVE THAN THE CURRENT STANDARD OF CARE ORAL IRON SUPPLEMENTATION AMONG POSTPARTUM WOMEN WITH MODERATE ANEMIA IN LOW- AND MIDDLE-INCOME COUNTRIES. IN ADDITION TO COMPARING OUTCOMES FOR TREATING ANEMIA, RESEARCHERS ARE ASSESSING TRIAL PARTICIPANTS FOR IMPORTANT SECONDARY OUTCOMES RELATED TO ANEMIA, PARTICULARLY POSTPARTUM DEPRESSION, WHICH CAN AFFECT MATERNAL QUALITY OF LIFE, FATIGUE, BREASTFEEDING INITIATION AND RETENTION RATES, AND INFANT-MOTHER BONDING. THE STUDY RESULTS ARE EXPECTED TO BE USEFUL FOR INFORMING NATIONAL HEALTH POLICIES AND PRACTICES, IMPROVING THE CARE OF WOMEN. ADVISING ON AN HISTORIC GLOBAL PANDEMIC TREATY AT AN HISTORIC GATHERING IN 2021, 173 MEMBER GOVERNMENTS OF THE WORLD HEALTH ORGANIZATION (WHO) RESOLVED TO NEGOTIATE AN INTERNATIONAL AGREEMENT ON PANDEMIC PREPAREDNESS AND RESPONSE. THE FNIH, IN PARTNERSHIP WITH WHO'S COLLABORATING CENTER AT GEORGETOWN UNIVERSITY'S O'NEILL INSTITUTE FOR NATIONAL AND GLOBAL HEALTH LAW, CONVENED DOZENS OF LEADING EXPERTS FROM AROUND THE WORLD TO PROVIDE TECHNICAL ADVICE AND LEARNINGS TO POLICYMAKERS, MEMBER STATES, AND THE PUBLIC. ON THE HEELS OF THE CONSORTIUM'S REPORT ON LEGAL TOOLS FOR PANDEMIC PREPAREDNESS, THE FNIH AND O'NEILL INSTITUTE ALSO BROUGHT TOGETHER THOUGHT LEADERS TO CONSIDER THE NATIONAL SOVEREIGNTY IMPLICATIONS OF A PANDEMIC INSTRUMENT, AND TO ANALYZE THE RANGE OF AGREEMENTS PREVIOUSLY DEPLOYED TO COORDINATE INTERNATIONAL ACTIVITY AND HOW THEY MIGHT INFORM A TREATY ADDRESSING CATASTROPHIC EPIDEMIC EVENTS. IN ADDITION, THE FNIH'S KEVIN A. KLOCK, WHO CO-CHAIRS THE INITIATIVE WITH THE O'NEILL INSTITUTE'S LAWRENCE O. GOSTIN, PUBLISHED A SERIES OF SUPPORTING PAPERS IN PROMINENT JOURNALS AND OUTLETS, INCLUDING THE LANCET, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, STAT, AND THINK GLOBAL HEALTH. A THIRD CONVENING, CO-LED WITH THE JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS (UNAIDS), COMMENCED IN THE SECOND HALF OF 2022 AND LED TO A 2023 REPORT CALLED ADVANCING A WORLD TOGETHER EQUITABLY, WHICH EXPLORES EXISTING MECHANISMS THAT ASSERT EQUITY AS A PRIORITY AND ANALYZED HOW THEY COULD BE INCORPORATED INTO A TREATY. |
| FORM 990, PART VI, SECTION A, LINE 1A | THE BOARD HAS AN EXECUTIVE COMMITTEE, WHICH CAN MAKE DECISIONS ON BEHALF OF THE BOARD (WITH SOME EXCEPTIONS) IN BETWEEN BOARD MEETINGS. |
| FORM 990, PART VI, SECTION B, LINE 11B | PRIOR TO THE SUBMISSION OF THE FOUNDATION FOR NIH'S FORM 990 TO THE INTERNAL REVENUE SERVICE, EACH VOTING MEMBER OF THE BOARD OF DIRECTORS SHALL BE PROVIDED WITH A COPY OF THE DRAFT FORM 990 AS APPROVED BY THE CHIEF FINANCIAL OFFICER. |
| FORM 990, PART VI, SECTION B, LINE 12C | DIRECTORS, OFFICERS AND EMPLOYEES ARE REQUIRED TO ANNUALLY SIGN A STATEMENT WHICH AFFIRMS THAT THEY HAVE: O RECEIVED A COPY OF THE CONFLICT OF INTEREST POLICY O READ, UNDERSTOOD AND AGREED TO COMPLY WITH THE POLICY O RECEIVED AND REVIEWED A LISTING OF CORPORATE AND FOUNDATION DONORS, CONTRACTORS, VENDORS, GRANTEES, PRINCIPAL INVESTIGATORS AND FINANCIAL INSTITUTIONS WITH WHOM THE FNIH HAS A CURRENT RELATIONSHIP O NO ACTUAL OR APPARENT CONFLICTS OF INTEREST OTHER THAN THOSE DISCLOSED IN THE STATEMENT. THEY MUST ALSO MAKE CERTAIN NOTIFICATIONS IN PARTICULAR CIRCUMSTANCES. THE CONFLICT OF INTEREST POLICY ALSO HAS MECHANISMS FOR HANDLING SUCH CONFLICTS. |
| FORM 990, PART VI, SECTION B, LINE 15 | THE COMPENSATION COMMITTEE OF THE BOARD REVIEWED AND CONCURRED WITH THE CEO'S DECISIONS ESTABLISHING AND ADJUSTING THE SENIOR EXECUTIVE TEAM'S ANNUAL SALARIES AND RELATED COMPENSATION DECISIONS. THE COMPENSATION COMMITTEE ALSO APPROVED THE COMPENSATION LEVEL OF THE CEO AND RELATED COMPENSATION DECISIONS. |
| FORM 990, PART VI, SECTION C, LINE 19 | ALL SUCH DOCUMENTS ARE AVAILABLE UPON REQUEST. IN ADDITION, THE GOVERNING DOCUMENTS AND FINANCIAL STATEMENTS ARE AVAILABLE ON THE FNIH WEBSITE. |
| FORM 990, PART XII, LINE 2C: | PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. |
| FORM 990, PART X, CASH & INVESTMENTS: | APPROXIMATELY $122 MILLION OF FNIH'S CASH AND INVESTMENTS ARE INVESTED IN HIGH QUALITY SHORT-TERM FIXED INCOME SECURITIES WHICH ARE COMMITTED TO FNIH'S RESTRICTED ASSETS. |
| Software ID: | |
| Software Version: |